Difference between revisions of "Alemtuzumab (Campath)"
Jump to navigation
Jump to search
Line 1: | Line 1: | ||
==General information== | ==General information== | ||
− | Class/mechanism: anti-CD52 cytolytic antibody<ref name="insert">[http://www.campath.com/pdfs/2009-08-Campath%20US%20PI.pdf Alemtuzumab (Campath) package insert]</ref><ref>[http://hemonc.org/docs/chemotherapypackageinsert/alemtuzumab.pdf Alemtuzumab (Campath) package insert (locally hosted backup)]</ref> | + | Class/mechanism: anti-CD52 cytolytic antibody.<ref name="insert">[http://www.campath.com/pdfs/2009-08-Campath%20US%20PI.pdf Alemtuzumab (Campath) package insert]</ref><ref>[http://hemonc.org/docs/chemotherapypackageinsert/alemtuzumab.pdf Alemtuzumab (Campath) package insert (locally hosted backup)]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information |
Revision as of 15:49, 29 November 2011
General information
Class/mechanism: anti-CD52 cytolytic antibody.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
Regimens
Standard format will be:
<acronym (if any)> <generic drug1, generic drug2, generic drug3, etc.> (disease)